Efficacy of 50 µg Versus 25 µg Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial
Fertility, Gynecology and Andrology · 2022
DOI: 10.5812/fga-129216 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Fertility, Gynecology and Andrology, 2022. Verfasst von Mehrnaz Valadan und 3 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Cervical ripening is the process of initiating labor in women with an unripe cervix. Vaginally administered prostaglandin E1 analog (misoprostol) has been promising in cervical ripening and labor induction. However, optimal dosage and dose-dependent adverse effects in this administration route need further clarification.
Objectives
This trial aimed to compare the efficacy and adverse effects of 50 mcg vs. 25 mcg of vaginal misoprostol in low-risk term pregnant women.
Methods
This double-blind, single-center, randomized clinical trial included 200 low-risk term pregnancies undergoing labor induction with a Bishop score of 2 or less. Patients were assigned randomly to receive 25 mcg or 50 mcg of vaginal misoprostol every six hours up to four times until the active phase of labor was reached. The primary outcome included time to vaginal delivery (latent and active phase of labor), and secondary outcomes included the total dosage of prescribed misoprostol, the need for oxytocin for labor augmentation, and the cesarean section rate.
Results
Misoprostol 50 micrograms resulted in a significantly shorter time in the first phase of labor (P-value = 0.002), the second phase of labor (P-value = 0.030), and the third phase of labor (P-value = 0.020). The number of administered misoprostol, the need for additional oxytocin, uterine hyperstimulation, cesarean delivery rate, Apgar score, umbilical artery pH, and neonatal intensive care unit (NICU) administration were statistically similar between the two groups.
Conclusions
This study showed that 50 mcg of vaginal misoprostol (vs. 25 mcg) for cervical ripening could reduce labor phase duration without significantly increasing adverse maternal and neonatal outcomes.
Zitieren
APA
Valadan, M., Raisian, Z., Feizabad, E., & Saedi, N. (2022). Efficacy of 50 µg Versus 25 µg Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial. Fertility, Gynecology and Andrology. https://doi.org/10.5812/fga-129216
Vancouver
Valadan M, Raisian Z, Feizabad E, Saedi N. Efficacy of 50 µg Versus 25 µg Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial. Fertility, Gynecology and Andrology. 2022. doi:10.5812/fga-129216
BibTeX
@article{Valadan2022,
author = {Valadan, Mehrnaz and Raisian, Zohre and Feizabad, Elham and Saedi, Nafiseh},
title = {Efficacy of 50 µg Versus 25 µg Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial},
journal = {Fertility, Gynecology and Andrology},
year = {2022},
doi = {10.5812/fga-129216}
}
EUVIMED